




The relative strengths and weaknesses of Regulus Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Regulus Therapeutics Inc compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 123% points. The greatest weakness of Regulus Therapeutics Inc is the variable Other Liabilities, reducing the Economic Capital Ratio by 60% points.

The company's Economic Capital Ratio, given in the ranking table, is 277%, being 57% points above the market average of 220%.

Input Variable	Value in 1000 USD
Assets, Current	98,929
Cost of Goods Sold	0
Intangible Assets	1,154
Liabilities, Current	12,768
Liabilities, Non-Current	767
Other Assets	125
Other Compr. Net Income	15
Other Expenses	237
Other Liabilities	27,890
Other Net Income	-4,707
Other Revenues	12,810
Property and Equipment	3,310
Research and Development	20,342
Selling, General and Administrative Expense	4,932

Output Variable	Value in 1000 USD
Assets	103,518
Liabilities	41,425
Expenses	25,511
Revenues	12,810
Stockholders Equity	62,093
Net Income	-17,408
Comprehensive Net Income	-17,400
BaseVar	93,993
ECR before Limited Liability	163%
Economic Capital Ratio	277%